<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:thr="http://purl.org/syndication/thread/1.0">
	<link rel="alternate" type="text/html" href="http://business.theatlantic.com/2009/07/extreme_health_care.php" />
	<link rel="self" type="application/atom+xml" href="http://business.theatlantic.com/atom.xml" />
	<id>tag:business.theatlantic.com,2009://3/tag:business.theatlantic.com,2009://3.21002-</id>
	<updated></updated>
	<title>Comments for Extreme Health Care</title>
	
	<generator uri="http://www.sixapart.com/movabletype/">Movable Type 4.24-en</generator>
	<entry>
		<id>tag:business.theatlantic.com,2009://3.21002</id>
		<link rel="alternate" type="text/html" href="http://business.theatlantic.com/2009/07/extreme_health_care.php" />
		<link rel="service.edit" type="application/atom+xml" href="http://business.theatlantic.com/mt-42/mt-atom.cgi/weblog/blog_id=3/entry_id=21002" title="Extreme Health Care" />
		<published>2009-07-09T20:37:53Z</published>
		<updated>2009-07-09T20:51:52Z</updated>
		<title>Extreme Health Care</title>
		<summary><![CDATA[Kevin Drum is skeptical that America does more in extremis than other healthcare programs: Boy, I'd sure like to see some backup for that.&nbsp; If by "extraordinary" Megan means the most extreme 0.001% of procedures, then maybe she's right.&nbsp; Maybe.&nbsp;...]]></summary>
		<author>
			<name>Megan McArdle</name>
			
		</author>
		
		<category term="Promo" />
		
		<content type="html" xml:lang="en" xml:base="http://business.theatlantic.com/">
			<![CDATA[Kevin Drum is <a href="http://www.motherjones.com/kevin-drum/2009/07/healthcare-extremis">skeptical</a> that America does more in extremis than other healthcare programs:<br /><br />
<blockquote>
<p>Boy, I'd sure like to see some backup for that.&nbsp; If by "extraordinary" Megan means the most extreme 0.001% of procedures, then maybe she's right.&nbsp; Maybe.&nbsp; But nothing I've read about Western European healthcare systems makes me believe that there's any substantial difference between the way they treat severe illnesses and the way we do it.&nbsp; And no systematic difference in success rates for such treatment either.&nbsp; Nor should this come as a surprise, since most extreme medicine is practiced on older patients, who are covered by a public plan both here and in Europe.</p></blockquote>]]>
			<![CDATA[If only Kevin had a subscription to The Atlantic--very reasonably priced at 19.95 a year--he would have found a hint in Virginia Postrel's article about <a href="http://www.theatlantic.com/doc/200903/postrel-drugs">Herceptin and early stage breast cancer</a>, which we ran in March.&nbsp; That article is about New Zealand, but the controversy over Herceptin was not limited to the Southern Hemisphere; Britain had a famous case involving the expensive cancer drug, in which a woman successfully used a combination of legal and media pressure to force the NIH to provide her with the drug for her early-stage breast cancer (she has since <a href="http://news.bbc.co.uk/2/hi/uk_news/england/wiltshire/7926320.stm">died</a>).&nbsp; Early stage HER2 positive breast cancer is hardly a 0.001% event--25% of breast cancers have the HER2 trait, and those tend to be the more aggressive kinds of cancer.&nbsp; The drug had already been offered for early stage cancers in the US for years, even though no one had definitive proof that it worked.<br /><br />This may be why--contrary to what Mr. Drum has apparently read--cancer survival rates in Europe <a href="http://www.medscape.com/viewarticle/561737">lag those in the US</a>.&nbsp; (Although this is complicated:&nbsp; we catch cancer earlier, because we're screening-test-mad, and some cancers just hang out for decades without killing you).&nbsp; At the highest macro level, life expectancy, Europe generally outperforms us.&nbsp; But it's not clear how much of that is health care, and how much things like our murder rate, and our famously sedentary lifestyles.&nbsp; When you drill down into many diseases, we outperform them.&nbsp; And many argue that we outperform them on hard-to-measure "lifestyle" issues:&nbsp; how fast your torn ACL gets repaired, how quickly (or whether) you get a hip replacement, etc.&nbsp; Such quality of life issues are nearly impossible to measure, though this hasn't stopped many people from trying.&nbsp; But I don't really trust the figures they generate.<br /><br />Europe gets a great deal out of all of this.&nbsp; We figure out what works, then they adopt it.&nbsp; But we get a great deal too--we get earlier access to controversial treatments, and our future generations get all the treatments we've discovered so far..]]>
		</content>
	</entry>

</feed>